Journal of Clinical and Cellular Immunology : Citations & Metrics Report
Articles published in Journal of Clinical and Cellular Immunology have been cited by esteemed scholars and scientists all around the world. Journal of Clinical and Cellular Immunology has got h-index 42, which means every article in Journal of Clinical and Cellular Immunology has got 42 average citations.
Following are the list of articles that have cited the articles published in Journal of Clinical and Cellular Immunology.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
30 | 31 | 30 | 59 | 28 | 11 | 35 | 56 | 95 | 105 | 101 | 105 | 64 | 15 | 3 |
Research, Review articles and Editorials |
2 | 13 | 8 | 23 | 18 | 8 | 25 | 35 | 54 | 86 | 79 | 35 | 23 | 14 | 3 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
20 | 18 | 22 | 22 | 10 | 3 | 10 | 21 | 39 | 6 | 9 | 7 | 1 | 1 | 0 |
Conference proceedings |
0 | 16 | 15 | 6 | 0 | 98 | 178 | 206 | 171 | 160 | 195 | 156 | 74 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
653 | 826 | 931 | 1079 | 1018 | 971 | 871 | 851 | 753 | 550 | 276 | 145 | 43 | 40 | 0 |
| Journal total citations count | 8361 |
| Journal impact factor | 24.12 |
| Journal 5 years impact factor | 31.14 |
| Journal cite score | 30.45 |
| Journal h-index | 42 |
| Journal h-index since 2019 | 32 |
Important citations (1511)
Tanaka t, ogata a, shima y, narazaki m, kumanogoh a, et al. (2012) therapeutic implications of tocilizumab, a humanized anti-interleukin-6 receptor antibody, for various immune-mediated diseases: an update review. current rheumatology reviews 8:209-226. |
|
Meszaros ec, malemud cj (2015) stat1 is constitutively activated in the t/c28a2 immortalized juvenile human chondrocyte line and stimulated by il-6 plus soluble il-6r. journal of clinical & cellular immunology 6. |
|
Malemud cj, blumenthal de (2014) protein kinase small molecule inhibitors for rheumatoid arthritis: medicinal chemistry/clinical perspectives. world journal of orthopedics 5: 496. |
|
michel l, larochelle c, prat a(2015) update on treatments in multiple sclerosis. la presse médicale 44:e137-51. |
|
Rush ca, maclean hj, freedman ms (2015). aggressive multiple sclerosis: proposed definition and treatment algorithm. nature reviews neurology 11:379-89. |
|
Gelfand jm, cotter j, klingman j, huang ej, cree ba (2014). massive cns monocytic infiltration at autopsy in an alemtuzumab-treated patient with nmo. neurology-neuroimmunology neuroinflammation 1:e34. |
|
Ziemssen t, de stefano n, sormani mp, van wijmeersch b, wiendl h, et al. (2015) optimizing therapy early in multiple sclerosis: an evidence-based view. multiple sclerosis and related disorders 4:460-9. |
|
Hartung hp, aktas o, boyko an (2015). alemtuzumab: a new therapy for active relapsing–remitting multiple sclerosis. multiple sclerosis journal 21:22-34. |
|
Mounika m. research & reviews: journal of pharmacology and toxicological studies. |
|
Verma sk, batra l, tuteja u (2016). a recombinant trivalent fusion protein f1–lcrv–hsp70 (ii) augments humoral and cellular immune responses and imparts full protection against yersinia pestis. frontiers in microbiology 7. |
|
Batra l, verma sk, nagar dp, saxena n, pathak p, et al.(2014) hsp70 domain ii of mycobacterium tuberculosis modulates immune response and protective potential of f1 and lcrv antigens of yersinia pestis in a mouse model. plos negl trop dis 8: e3322. |
|
Tanaka t, narazaki m, masuda k, kishimoto t (2013) interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. inflammation and regeneration 33: 054-65. |
|
Malemud cj (2013) intracellular signaling pathways in rheumatoid arthritis. journal of clinical & cellular immunology 4: 160. |
|
Tanaka t, narazaki m, kishimoto t (2014) il-6 in inflammation, immunity, and disease. cold spring harbor perspectives in biology 6: a016295. |
|
Tanaka t, kishimoto t (2012) targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. int j biol sci 8: 1227-1236. |
|
Meszaros ec, dahoud w, mesiano s, malemud cj. take a look at the recent articles. |
|
Pandey s, rai n, rawat p, ahmad fj, talegaonkar s (2016) nanofacilitated synergistic treatment for rheumatoid arthritis: a ‘three-pronged’approach. medical hypotheses 92: 44-47. |
|
Meszaros ec, dahoud w, mesiano s, malemud cj (2015) blockade of recombinant human il-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the c28/i2 immortalized human chondrocyte cell line. integrative molecular medicine 2: 304. |
|
Malemud cj (2015) chondrocyte apoptosis in rheumatoid arthritis: is preventive therapy possible?. immunotherapy (los angeles, calif.) 1. |
|
Malemud cj (2013) intracellular signaling pathways in rheumatoid arthritis. journal of clinical & cellular immunology 4: 160. |
|